Eva Fortea Verdejo
Stock Analyst at Wells Fargo
(4.78)
# 533
Out of 4,407 analysts
88
Total ratings
65.7%
Success rate
37.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eva Fortea Verdejo
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NUVL Nuvalent | Downgraded: Hold | $116 → $124 | $123.25 | +0.61% | 3 | Jun 10, 2026 | |
| CELC Celcuity | Rated: Buy | $183 → $166 | $88.55 | +87.46% | 5 | Jun 3, 2026 | |
| ZYME Zymeworks | Maintained: Buy | $34 | $22.88 | +48.60% | 6 | Jun 1, 2026 | |
| GMAB Genmab | Rated: Buy | $40 | $25.06 | +59.65% | 6 | Jun 1, 2026 | |
| RVMD Revolution Medicines | Rated: Buy | $167 | $153.87 | +8.53% | 10 | Jun 1, 2026 | |
| BCAX Bicara Therapeutics | Rated: Hold | $16 | $21.69 | -26.23% | 10 | Jun 1, 2026 | |
| RLAY Relay Therapeutics | Maintained: Buy | $21 | $14.81 | +41.80% | 9 | May 19, 2026 | |
| ZNTL Zentalis Pharmaceuticals | Rated: Hold | $5 | $3.75 | +33.33% | 1 | May 13, 2026 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintained: Buy | $53 → $57 | $51.89 | +9.85% | 14 | Apr 29, 2026 | |
| IDYA IDEAYA Biosciences | Maintained: Buy | $44 → $48 | $28.98 | +65.63% | 5 | Apr 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $60 | $28.97 | +107.11% | 3 | Apr 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $8 → $27 | $28.80 | -6.25% | 2 | Mar 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $30 → $23 | $23.80 | -3.36% | 8 | Feb 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $27 | $12.33 | +118.98% | 6 | Oct 23, 2025 |
Nuvalent
Jun 10, 2026
Downgraded: Hold
Price Target: $116 → $124
Current: $123.25
Upside: +0.61%
Celcuity
Jun 3, 2026
Rated: Buy
Price Target: $183 → $166
Current: $88.55
Upside: +87.46%
Zymeworks
Jun 1, 2026
Maintained: Buy
Price Target: $34
Current: $22.88
Upside: +48.60%
Genmab
Jun 1, 2026
Rated: Buy
Price Target: $40
Current: $25.06
Upside: +59.65%
Revolution Medicines
Jun 1, 2026
Rated: Buy
Price Target: $167
Current: $153.87
Upside: +8.53%
Bicara Therapeutics
Jun 1, 2026
Rated: Hold
Price Target: $16
Current: $21.69
Upside: -26.23%
Relay Therapeutics
May 19, 2026
Maintained: Buy
Price Target: $21
Current: $14.81
Upside: +41.80%
Zentalis Pharmaceuticals
May 13, 2026
Rated: Hold
Price Target: $5
Current: $3.75
Upside: +33.33%
Kiniksa Pharmaceuticals International,
Apr 29, 2026
Maintained: Buy
Price Target: $53 → $57
Current: $51.89
Upside: +9.85%
IDEAYA Biosciences
Apr 14, 2026
Maintained: Buy
Price Target: $44 → $48
Current: $28.98
Upside: +65.63%
Apr 14, 2026
Maintained: Buy
Price Target: $60
Current: $28.97
Upside: +107.11%
Mar 24, 2026
Upgraded: Buy
Price Target: $8 → $27
Current: $28.80
Upside: -6.25%
Feb 12, 2026
Downgraded: Hold
Price Target: $30 → $23
Current: $23.80
Upside: -3.36%
Oct 23, 2025
Maintained: Buy
Price Target: $27
Current: $12.33
Upside: +118.98%